JGC
LPCN icon

J. Goldman & Co’s Lipocine LPCN Stock Holding History

J. Goldman & Co’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$337K Buy
+42,170
New +$367K 0.01% 552
2019
Q1 		– Sell
-14,025
Closed -$310K – 298
2018
Q4 		$310K Sell
14,025
-15,425
-52% -$358K 0.02% 216
2018
Q3 		$691K Sell
29,450
-12,609
-30% -$310K 0.05% 208
2018
Q2 		$930K Buy
+42,059
New +$1M 0.05% 260
2015
Q3 		– Sell
-4,412
Closed -$643K – 277
2015
Q2 		$643K Sell
4,412
-882
-17% -$109K 0.04% 200
2015
Q1 		$621K Buy
+5,294
New +$576K 0.04% 243

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

J. Goldman & Co's LPCN Position: Q1 2026 in Review

J. Goldman & Co opened a new position in Lipocine (LPCN) in Q1 2026: 42,170 shares worth $337K. The stake represents 0.01% of the portfolio and ranks #552 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in LPCN as recently as Q4 2018.

J. Goldman & Co first reported a position in LPCN in Q1 2015 and has held it in 6 quarters since. The position peaked at $930K in Q2 2018. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • J. Goldman & Co held 42,170 shares of Lipocine worth $337K as of Q1 2026.
  • Lipocine was a new J. Goldman & Co position in Q1 2026.
  • Lipocine made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #552 holding.
  • J. Goldman & Co first reported a position in Lipocine in Q1 2015 and has held it in 6 quarters since.
  • J. Goldman & Co's Lipocine position peaked at $930K in Q2 2018.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.